AOD-9604 and 100+ compounds listed in clinical trials gateway digest
Background
Clinical drug development requires centralised tracking of compounds progressing through trials across dozens of disease areas. Databases such as the Prous Science Integrity portal aggregate trial-stage data for hundreds of investigational agents simultaneously, spanning metabolic, oncologic, cardiovascular, and immunologic pipelines. AOD-9604, a peptide fragment derived from the C-terminus of human growth hormone, was under investigation during this period for metabolic and obesity-related indications, distinguishing it from its parent molecule by a proposed lack of IGF-1-axis activity. Consolidated gateway publications of this type serve as a snapshot reference for researchers and clinicians navigating a fragmented trial landscape, providing a single indexed source for compound status without requiring individual registry searches.
Study Design
The publication compiled clinical trial data retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, a drug discovery and development portal. No original experimental design, patient cohort, dosing protocol, or control arm is described — this is a database-derived index article. Compounds were selected editorially and presented in tabular form. AOD-9604 was included among the tracked investigational agents without further methodological detail provided in the available abstract.
Results
The abstract does not report quantitative outcomes, efficacy data, safety signals, or trial-phase results for any individual compound, including AOD-9604. The publication functions as a registry index rather than a results paper. No p-values, fold-changes, responder rates, or dose-response data are presented.
AOD-9604 is listed as one of over 100 investigational compounds tracked in this clinical trials gateway issue, with no outcome data reported in the abstract.
Key Findings
- AOD-9604 listed as an actively tracked investigational compound in the Prous Science Integrity clinical trials database.
- Over 100 compounds catalogued in this single gateway issue spanning oncology, metabolic, cardiovascular, and immunologic areas.
- No quantitative outcomes or trial-phase results reported for any listed compound in the available abstract.
Why It Matters
AOD-9604's inclusion in a formal clinical trials gateway confirms it held active investigational status at the time of publication, meaning regulatory and sponsor-level interest was sufficient to warrant indexed tracking. For clinicians and researchers, this type of compendium entry signals that AOD-9604 had advanced beyond preclinical stages and was considered alongside mainstream pharmaceutical candidates. However, no dosing, safety, or efficacy conclusions can be drawn from this listing alone. Anyone evaluating AOD-9604 for clinical or research use must consult primary trial registries and completed study reports, not gateway index entries, for protocol-relevant data.
